Our findings provide further insights into B-ALL cell biology and survival mechanisms and identify MEK and BCL-2/BCL-XL as targets that could be exploited for effective management of this disease. Here, BCL2L1 is linked to precursor B-cell acute lymphoblastic leukemia.